Please login to the form below

Not currently logged in

UK CROs to offer drug discovery services to Nordic businesses

Will head to Copenhagen in March for market visit

test tubesUK-based contract research organisations (CROs) will head to Denmark next month to discuss how collaborative outsourcing can overcome R&D scientific challenges.

The UKTI supported market visit, entitled 'The Changing Face of Pharmaceutical Discovery and Development – A Collaborative CRO Approach' is aimed at R&D scientists, project leaders and resource managers and will give life science research companies in the Nordic region the opportunity to converse with CROs.

The presentations will have a specific focus on Scandinavia, with guest speakers including Dr Daniel Greve from Leo Pharma and Dr Richard Weaver, who is managing director of XenoGesis.

Commenting on the discussion, Weaver said: “Attracting new business is essential to our success. By having this collaborative approach and offering a comprehensive range of drug discovery activities, we are confident in providing an attractive proposition to Nordic countries seeking support with their research projects.

“Clients recognise the value of specialist expertise and appreciate the quality and turnaround speed that dedicated organisations can provide.”

The companies attending cover an expansion area in drug discovery activities and product development, with Aurelia BioScience, Reach Separations, Molecular Profiles and Biopta all attending and discussing their individual work.

Peter Ridgway, from Reach Separations, added: “We have a strong understanding of each others capabilities and how we can work together effectively to become more competitive.

“As companies become more confident with outsourcing, the way they approach it is evolving. The need for a collaborative approach of bringing services together in this way is only going to grow.”

The UK CROs' visit takes place on March 25 at the residence of the British Ambassador in Copenhagen.

Article by
Kirstie Pickering

17th February 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...